Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022106363> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2022106363 endingPage "485" @default.
- W2022106363 startingPage "482" @default.
- W2022106363 abstract "The development of an inhibitor against Factor VIII is an important complication of haemophilia and occurs in approximately 31% of patients [1]. Despite various approaches to their management, the presence of these inhibitors remains a major cause of morbidity and mortality. Inhibitors may be low level [<5 Bethesda Units (BU)] or high level [>10 BU]. Low-level inhibitors usually remain low and do not respond to administered factor VIII with a rise of the inhibitor titre; high-level inhibitors, in contrast, are characterized by a rapid rise in titre following treatment with factor VIII. Modalities of treatment of acute bleeding episodes in patients with inhibitors include 'overcoming' the inhibitor with very large doses of factor VIII, 'bypassing' the inhibitor blockade with products such as activated prothrombin complex concentrates or recombinant factor VIIa, 'removing' the inhibitor by plasmapheresis or immunoabsorption and 'repressing' it with immunosuppressive drugs and immune tolerance induction. An alternative approach is to use a porcine factor VIII concentrate which does not cross-react with the human factor VIII inhibitor. Following treatment with porcine factor VIII, functional factor VIII can be detected and the therapeutic levels correlate with cessation of bleeding. The use of porcine factor VIII may, however, result in the development of antiporcine factor VIII antibodies, limiting its use. Experience in patients with high-titre inhibitors indicates that porcine factor VIII therapy could be used in the presence of factor VIII inhibitors [2-11], including inhibitors to porcine factor VIII [5,7], and that haemostasis may be obtained in the absence of detectable levels of circulating factor VIII [7,11]." @default.
- W2022106363 created "2016-06-24" @default.
- W2022106363 creator A5055404213 @default.
- W2022106363 creator A5085098019 @default.
- W2022106363 date "2000-09-01" @default.
- W2022106363 modified "2023-09-29" @default.
- W2022106363 title "Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII" @default.
- W2022106363 cites W130993888 @default.
- W2022106363 cites W1497282221 @default.
- W2022106363 cites W1578596706 @default.
- W2022106363 cites W2027280365 @default.
- W2022106363 cites W2050510640 @default.
- W2022106363 cites W2056634959 @default.
- W2022106363 cites W2118501220 @default.
- W2022106363 cites W2157282995 @default.
- W2022106363 cites W2411143687 @default.
- W2022106363 cites W2413894884 @default.
- W2022106363 cites W2429658547 @default.
- W2022106363 cites W2438513900 @default.
- W2022106363 doi "https://doi.org/10.1046/j.1365-2516.2000.00403.x" @default.
- W2022106363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11012689" @default.
- W2022106363 hasPublicationYear "2000" @default.
- W2022106363 type Work @default.
- W2022106363 sameAs 2022106363 @default.
- W2022106363 citedByCount "14" @default.
- W2022106363 countsByYear W20221063632012 @default.
- W2022106363 countsByYear W20221063632013 @default.
- W2022106363 countsByYear W20221063632021 @default.
- W2022106363 crossrefType "journal-article" @default.
- W2022106363 hasAuthorship W2022106363A5055404213 @default.
- W2022106363 hasAuthorship W2022106363A5085098019 @default.
- W2022106363 hasConcept C126322002 @default.
- W2022106363 hasConcept C141071460 @default.
- W2022106363 hasConcept C159654299 @default.
- W2022106363 hasConcept C203014093 @default.
- W2022106363 hasConcept C2777232031 @default.
- W2022106363 hasConcept C2778385053 @default.
- W2022106363 hasConcept C2778842783 @default.
- W2022106363 hasConcept C2778961111 @default.
- W2022106363 hasConcept C2781221834 @default.
- W2022106363 hasConcept C32611913 @default.
- W2022106363 hasConcept C71924100 @default.
- W2022106363 hasConcept C98274493 @default.
- W2022106363 hasConceptScore W2022106363C126322002 @default.
- W2022106363 hasConceptScore W2022106363C141071460 @default.
- W2022106363 hasConceptScore W2022106363C159654299 @default.
- W2022106363 hasConceptScore W2022106363C203014093 @default.
- W2022106363 hasConceptScore W2022106363C2777232031 @default.
- W2022106363 hasConceptScore W2022106363C2778385053 @default.
- W2022106363 hasConceptScore W2022106363C2778842783 @default.
- W2022106363 hasConceptScore W2022106363C2778961111 @default.
- W2022106363 hasConceptScore W2022106363C2781221834 @default.
- W2022106363 hasConceptScore W2022106363C32611913 @default.
- W2022106363 hasConceptScore W2022106363C71924100 @default.
- W2022106363 hasConceptScore W2022106363C98274493 @default.
- W2022106363 hasIssue "5" @default.
- W2022106363 hasLocation W20221063631 @default.
- W2022106363 hasLocation W20221063632 @default.
- W2022106363 hasOpenAccess W2022106363 @default.
- W2022106363 hasPrimaryLocation W20221063631 @default.
- W2022106363 hasRelatedWork W1972589220 @default.
- W2022106363 hasRelatedWork W2005593348 @default.
- W2022106363 hasRelatedWork W2055566045 @default.
- W2022106363 hasRelatedWork W2062879576 @default.
- W2022106363 hasRelatedWork W2074293733 @default.
- W2022106363 hasRelatedWork W2086453788 @default.
- W2022106363 hasRelatedWork W2087867949 @default.
- W2022106363 hasRelatedWork W2145799825 @default.
- W2022106363 hasRelatedWork W2151235372 @default.
- W2022106363 hasRelatedWork W3026906757 @default.
- W2022106363 hasVolume "6" @default.
- W2022106363 isParatext "false" @default.
- W2022106363 isRetracted "false" @default.
- W2022106363 magId "2022106363" @default.
- W2022106363 workType "article" @default.